熱門資訊> 正文
Invivyd提供Pemgarda 2024净产品收入指导
2024-04-05 04:16
- Invivyd (NASDAQ:IVVD) announced that PEMGARDA is now available for purchase in the U.S. for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise.
- The company provided PEMGARDA net product revenue guidance in the range of $150 million to $200 million for the full year 2024.
- Based on this anticipated net product revenue and our continued optimization of operating expenses, we expect to end 2024 with at least $55 million in cash and cash equivalents.
- Source: Press Release
More on Adagio Therapeutics
- Morgan Stanley ups Invivyd to overweight, cites FDA EUA decision
- Invivyd stock soars on FDA EUA for COVID-19 prophylaxis drug
- Seeking Alpha’s Quant Rating on Adagio Therapeutics
- Historical earnings data for Adagio Therapeutics
- Financial information for Adagio Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
